Matches in Wikidata for { <http://www.wikidata.org/entity/Q82046436> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- Q82046436 description "artículu científicu espublizáu n'ochobre de 2008" @default.
- Q82046436 description "im Oktober 2008 veröffentlichter wissenschaftlicher Artikel" @default.
- Q82046436 description "scientific article published on 01 October 2008" @default.
- Q82046436 description "wetenschappelijk artikel" @default.
- Q82046436 description "наукова стаття, опублікована в жовтні 2008" @default.
- Q82046436 name "A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects" @default.
- Q82046436 name "A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects" @default.
- Q82046436 type Item @default.
- Q82046436 label "A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects" @default.
- Q82046436 label "A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects" @default.
- Q82046436 prefLabel "A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects" @default.
- Q82046436 prefLabel "A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects" @default.
- Q82046436 P1433 Q82046436-E44094D7-4A52-41E8-A889-3F6DCBF1D025 @default.
- Q82046436 P1476 Q82046436-E34753FC-711C-4E6C-BFF3-03FC38D0EF7D @default.
- Q82046436 P2093 Q82046436-0689A5F8-263F-480E-9C35-72F07CA7DC50 @default.
- Q82046436 P2093 Q82046436-1A87A3DD-A668-4F95-978D-08413B0193A2 @default.
- Q82046436 P2093 Q82046436-58ECD1D1-7EA8-46E1-B712-EF81039294A3 @default.
- Q82046436 P2093 Q82046436-64C1C666-9313-4C99-B26F-72763F73A7C1 @default.
- Q82046436 P2093 Q82046436-7E262D58-E606-44D8-9856-490F0F667CA2 @default.
- Q82046436 P2093 Q82046436-8C5C049A-5A38-4149-BCE2-BA074FF8B5B0 @default.
- Q82046436 P2093 Q82046436-C1DC2648-5F5A-4DCE-B0D3-CBC548DCE6B8 @default.
- Q82046436 P2093 Q82046436-C580D8DA-AFDF-4A9D-997D-435E6A7330FD @default.
- Q82046436 P2093 Q82046436-D580F963-DB46-453F-9D39-643E749185F6 @default.
- Q82046436 P2093 Q82046436-DD3D6F06-618F-48F3-8D54-BBEDF44B8A2E @default.
- Q82046436 P2093 Q82046436-E2974CB6-5B6C-4234-9AE8-8CBC3F6B6C80 @default.
- Q82046436 P2093 Q82046436-F48C2F35-24B2-4386-8C6F-BC6F1F79228A @default.
- Q82046436 P304 Q82046436-F09F51CD-6580-4335-926C-1CE283DF4F36 @default.
- Q82046436 P31 Q82046436-30939CE1-A1E9-4693-8367-AF73D9C63A6D @default.
- Q82046436 P356 Q82046436-AF7B8FF3-B36B-461F-B6AB-69FD7197A430 @default.
- Q82046436 P433 Q82046436-4095A6ED-64E3-412D-A647-A449F26A70AD @default.
- Q82046436 P478 Q82046436-B55523D6-0A66-49A0-ACE6-939CBA391C81 @default.
- Q82046436 P50 Q82046436-ABFB0E25-0AB4-417A-9D8C-8F739A5A040A @default.
- Q82046436 P577 Q82046436-AD64E889-BFD3-4667-9B62-F339B881320F @default.
- Q82046436 P698 Q82046436-301BAAAD-BADC-48C3-8189-17AB655B2A94 @default.
- Q82046436 P921 Q82046436-838BA4BC-8AC3-4F2F-9C3E-1F109FCAB350 @default.
- Q82046436 P921 Q82046436-8822616F-94B2-40CF-A3B2-358FDE336F51 @default.
- Q82046436 P356 0091270008322907 @default.
- Q82046436 P698 18812609 @default.
- Q82046436 P1433 Q7743562 @default.
- Q82046436 P1476 "A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects" @default.
- Q82046436 P2093 "Adam Cohen" @default.
- Q82046436 P2093 "Bart Frederick" @default.
- Q82046436 P2093 "Bruce Miller" @default.
- Q82046436 P2093 "Esther Bouman-Thio" @default.
- Q82046436 P2093 "Haishan Jang" @default.
- Q82046436 P2093 "Hugh Davis" @default.
- Q82046436 P2093 "Jennifer Yohrling" @default.
- Q82046436 P2093 "John Getsy" @default.
- Q82046436 P2093 "Kari Franson" @default.
- Q82046436 P2093 "Qun Jiao" @default.
- Q82046436 P2093 "Stanley Marciniak" @default.
- Q82046436 P2093 "Stephen A Bai" @default.
- Q82046436 P304 "1197-1207" @default.
- Q82046436 P31 Q13442814 @default.
- Q82046436 P356 "10.1177/0091270008322907" @default.
- Q82046436 P433 "10" @default.
- Q82046436 P478 "48" @default.
- Q82046436 P50 Q88913167 @default.
- Q82046436 P577 "2008-10-01T00:00:00Z" @default.
- Q82046436 P698 "18812609" @default.
- Q82046436 P921 Q323936 @default.
- Q82046436 P921 Q725307 @default.